Investment analysts and portfolio managers look into their crystal balls to predict the best-performing stocks for the year ahead.
After failing to sell its NZ assets, OMV agrees new contract for Pohokura gas out to 2032.
US respiratory data and currency movements are providing tailwinds.
A preliminary injunction would allow reimbursement to continue in the US.
Identity of potential buyers for phosphate mining and exploration permits is unclear.
Singaporean CDL offers $2.25 for 24% of hotel company it doesn’t already own – well below MCK’s net tangible asset value of $3.36 per share.
The takeover battle has seen the company’s value double since November.
The company admits the Novitas decision is a ‘significant blow’ but says it’s not a knockout.
The cancer diagnostics company has gone into a trading halt following an adverse decision on reimbursement of its US bladder tests.
The dual-listed retailer says it’s yet to see any marked improvements in consumer confidence following recent cuts to interest rates.
